» Articles » PMID: 37035400

Tumor Dormancy is Closely Related to Prognosis Prediction and Tumor Immunity in Neuroblastoma

Overview
Journal Transl Pediatr
Specialty Pediatrics
Date 2023 Apr 10
PMID 37035400
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neuroblastoma (NB), which is the most frequent and fatal solid tumor in early childhood, lacks an accurate approach to prevent or forecast its recurrence. Dormant NB cells are responsible for metastasis, drug resistance, and suppressive activity in the immune system. However, there is a lack of systematic research on the interaction between dormancy and NB prognosis and its potential associations with tumor immunity.

Methods: We downloaded NB gene expression data and clinical information from the Gene Expression Omnibus and ArrayExpres databases. Based on consensus clustering of the expression of dormancy-associated genes, the NB samples were classified into different groups, and differentially expressed genes (DEGs) were explored in each group. Functional analyses of DEGs were performed, followed by the establishment of a predictive dormancy signature and the assessment of tumor immunity. Finally, sex, age, International Neuroblastoma Staging System (INSS) stage, and status were identified as independent overall survival-related variables, which were incorporated into the nomogram.

Results: A dormancy-associated gene signature, including , , , , , and was established. The gene signature showed a strong correlation with NB immune infiltration and capacity to predict NB patient prognosis. A nomogram including status, INSS stage, age and gene signature risk score was established which further divided NB into high, medium and low-risk groups. This nomogram had certain guiding significance in decision-making for clinical treatment.

Conclusions: Our results suggested that the 6-gene genetic signature for NB based on dormancy could predict NB survival and response to immunotherapy.

Citing Articles

Segmental chromosome aberrations as a prognostic factor of neuroblastoma: a meta-analysis and systematic review.

Geng J, Wang X, Zhao L, Zhang J, Niu H Transl Pediatr. 2024; 13(10):1789-1798.

PMID: 39524401 PMC: 11543117. DOI: 10.21037/tp-24-200.


Development and validation of a novel stemness-related prognostic model for neuroblastoma using integrated machine learning and bioinformatics analyses.

Xia Y, Wang C, Li X, Gao M, Hogg H, Tunthanathip T Transl Pediatr. 2024; 13(1):91-109.

PMID: 38323183 PMC: 10839279. DOI: 10.21037/tp-23-582.

References
1.
Kobayashi A, Okuda H, Xing F, Pandey P, Watabe M, Hirota S . Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 2011; 208(13):2641-55. PMC: 3244043. DOI: 10.1084/jem.20110840. View

2.
Twist C, Schmidt M, Naranjo A, London W, Tenney S, Marachelian A . Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019; 37(34):3243-3255. PMC: 6881103. DOI: 10.1200/JCO.19.00919. View

3.
Kushner B, Helson L, Lane J, HAJDU S . Metastatic neuroblastoma after 52 years of apparent dormancy. N Engl J Med. 1986; 315(3):196-7. DOI: 10.1056/NEJM198607173150318. View

4.
Park J, Cheung N . Targets and Antibody Formats for Immunotherapy of Neuroblastoma. J Clin Oncol. 2020; 38(16):1836-1848. PMC: 7255979. DOI: 10.1200/JCO.19.01410. View

5.
Laut A, Dorneburg C, Furstberger A, Barth T, Kestler H, Debatin K . CHD5 inhibits metastasis of neuroblastoma. Oncogene. 2021; 41(5):622-633. PMC: 8799470. DOI: 10.1038/s41388-021-02081-0. View